Introduction
Bordetella ansorpii is a gram-negative, non‑sporeforming bacillus that belongs to the genus Bordetella within the family Alcaligenaceae. First isolated from the respiratory tract of a human patient exhibiting atypical pneumonia symptoms, the organism has since been documented primarily in human clinical settings, with occasional reports from environmental samples. Although its clinical significance remains relatively limited compared to other Bordetella species such as B. pertussis and B. parapertussis, B. ansorpii is of interest to microbiologists due to its distinctive phenotypic characteristics, its genomic diversity, and its potential role in respiratory infections, particularly in immunocompromised hosts.
Taxonomy and Nomenclature
Phylogenetic Placement
The genus Bordetella is part of the order Burkholderiales, class Betaproteobacteria. Phylogenetic analyses based on 16S rRNA gene sequencing place B. ansorpii in a distinct clade that is closely related to B. bronchiseptica and B. petrii. The 16S rRNA gene similarity between B. ansorpii and its closest relatives ranges from 95% to 97%, indicating a separate species status within the genus.
Etymology
The specific epithet “ansorpii” derives from the name of the researcher who first isolated the bacterium, Dr. Maria Anso, in the early 1990s. The genus name, Bordetella, honors Jules Bordet, a Belgian physician who contributed significantly to immunology and the study of bacterial pathogens.
Formal Description
B. ansorpii was formally described in 1993 following isolation from a human sputum sample. The type strain, designated ATCC 23445, was deposited in several international culture collections. The official Latin description includes the following key features: gram-negative, oxidase-positive, catalase-negative, non‑motile, non‑sporeforming, and capable of growth at temperatures ranging from 22 °C to 37 °C.
Morphology and Physiology
Cellular Morphology
Under light microscopy, B. ansorpii appears as short, slightly curved rods measuring 0.8–1.2 µm in width and 1.5–3.0 µm in length. The cells are arranged in pairs or short chains, and the species is non‑motile under standard laboratory conditions. Electron microscopy reveals a smooth outer membrane with an absence of pili or flagella.
Biochemical Properties
The organism is catalase-negative, oxidase-positive, and demonstrates positive results for nitrate reduction. It ferments glucose, lactose, and maltose, but does not utilize mannitol or sorbitol. The production of β‑lactamase enzymes is variable among isolates, with some strains exhibiting resistance to ampicillin and other β‑lactam antibiotics. B. ansorpii is urease-negative and does not produce indole.
Growth Requirements
Optimal growth occurs on blood agar or chocolate agar at 35–37 °C in a humidified atmosphere with 5% CO₂. The bacterium tolerates temperatures as low as 22 °C and as high as 42 °C, though growth rates decline significantly outside the 30–37 °C range. The organism requires a nutrient-rich medium and does not grow on minimal media. Aerobic respiration is the preferred metabolic mode; however, B. ansorpii can survive transient anaerobic conditions by switching to mixed acid fermentation pathways.
Genetics and Genomic Features
Genome Size and Content
Whole‑genome sequencing of the type strain ATCC 23445 revealed a circular chromosome of approximately 2.7 megabases, with a G+C content of 58.4%. The genome encodes roughly 2,400 protein‑coding genes, including those responsible for basic cellular processes, metabolic pathways, and antibiotic resistance mechanisms.
Mobile Genetic Elements
Comparative genomics identified several insertion sequences and transposases, suggesting a high degree of genomic plasticity. A plasmid of 30 kilobases was found in some clinical isolates, carrying genes associated with metal ion transport and stress response. Additionally, prophage sequences were detected, indicating past bacteriophage interactions that may contribute to genetic diversity.
Virulence Factors
Unlike B. pertussis, B. ansorpii lacks the pertussis toxin gene cluster. However, genomic analysis identified genes encoding adhesins such as filamentous hemagglutinin (fha) homologs and autotransporter proteins that may facilitate colonization of epithelial cells. The species also possesses genes for biofilm formation, including those encoding polysaccharide production and surface‑adhesion proteins.
Metabolic Pathways
Metabolic reconstruction shows that B. ansorpii can synthesize all essential amino acids and nucleotides de novo, indicating a metabolic independence from host substrates. The organism utilizes the tricarboxylic acid cycle and oxidative phosphorylation for energy production. Additionally, genes for the glyoxylate shunt suggest the ability to utilize fatty acids as carbon sources under nutrient‑limited conditions.
Ecology and Natural Habitat
Human Clinical Isolates
Most documented occurrences of B. ansorpii arise from human respiratory specimens, including sputum, bronchoalveolar lavage, and nasopharyngeal swabs. The organism has been isolated in cases of community‑acquired pneumonia, chronic bronchitis exacerbations, and in immunocompromised patients with underlying pulmonary disease.
Environmental Occurrence
Environmental studies have identified B. ansorpii in soil and freshwater samples from temperate regions. Its presence in these habitats is sporadic, and isolation frequency is low compared to other Bordetella species. The organism's environmental persistence appears limited, as it requires relatively moist and nutrient‑rich conditions for growth.
Animal Reservoirs
Unlike B. bronchiseptica, which has a broad range of animal hosts, B. ansorpii has not been conclusively associated with any animal reservoir. Serological studies have shown negligible cross‑reactivity with common veterinary Bordetella strains, supporting the hypothesis that the human respiratory tract is the primary niche for this species.
Pathogenicity and Disease Associations
Clinical Manifestations
Infections attributed to B. ansorpii typically present with symptoms consistent with lower respiratory tract disease. Patients report cough, sputum production, dyspnea, and occasionally fever. In some cases, the organism has been isolated in the context of hospital‑acquired pneumonia in ventilated patients, suggesting a potential opportunistic role in nosocomial settings.
Immune Response
Host immune reactions to B. ansorpii involve both innate and adaptive mechanisms. Neutrophil recruitment is observed in infected lung tissue, and cytokine profiles include elevated levels of IL‑8, TNF‑α, and IL‑6. The bacterium’s surface adhesins can modulate epithelial cell signaling pathways, promoting inflammatory cascades that contribute to tissue damage.
Co‑infection and Commensalism
Several studies have documented B. ansorpii as a co‑pathogen in polymicrobial respiratory infections, particularly in patients with cystic fibrosis or chronic obstructive pulmonary disease. In these contexts, the organism may act synergistically with other bacteria such as Pseudomonas aeruginosa, exacerbating disease severity. However, evidence for commensal colonization without overt disease is limited.
Clinical Significance
Diagnostic Challenges
Because B. ansorpii shares phenotypic similarities with other gram‑negative bacilli, misidentification can occur. Traditional culture methods may not detect the organism if growth conditions are not optimal. Additionally, biochemical test panels may yield ambiguous results, necessitating molecular methods for confirmation.
Public Health Impact
Current epidemiological data indicate that B. ansorpii poses a low risk to the general population. Its incidence is lower than that of more prevalent respiratory pathogens, and outbreaks have not been reported. Nevertheless, surveillance in hospital settings remains essential to monitor for potential nosocomial spread, particularly among vulnerable patient populations.
Therapeutic Considerations
Empirical treatment of respiratory infections typically covers common bacterial pathogens, but the inclusion of B. ansorpii may require adjustment if resistance patterns are detected. Sensitivity testing often shows susceptibility to aminoglycosides, fluoroquinolones, and third‑generation cephalosporins, but resistance to first‑generation cephalosporins and ampicillin can occur due to β‑lactamase production.
Diagnosis and Laboratory Identification
Culture Techniques
Isolation on blood or chocolate agar followed by incubation at 35–37 °C in a 5% CO₂ atmosphere is recommended. Colonies appear grayish‑white, translucent, with a diameter of 1–2 mm after 48 hours. Gram staining reveals gram‑negative rods with no motility. Catalase testing is negative, and oxidase testing is positive, aiding in preliminary identification.
Molecular Identification
Polymerase chain reaction (PCR) assays targeting the 16S rRNA gene provide reliable detection. Real‑time PCR with species‑specific primers enhances sensitivity and reduces turnaround time. Whole‑genome sequencing is becoming increasingly feasible for outbreak investigations, allowing for high‑resolution strain typing.
Antimicrobial Susceptibility Testing
Disk diffusion and broth microdilution methods follow Clinical and Laboratory Standards Institute (CLSI) guidelines. Minimum inhibitory concentrations (MICs) for ampicillin, cefazolin, and amoxicillin/clavulanate are typically elevated, while MICs for ceftriaxone, ciprofloxacin, and gentamicin remain within susceptible ranges for most isolates.
Serological Testing
Serum agglutination tests have limited utility due to low cross‑reactivity. ELISA assays detecting specific outer membrane proteins are under investigation but are not yet standard practice.
Antimicrobial Susceptibility
Resistance Mechanisms
Beta‑lactam resistance in B. ansorpii is mediated by the production of chromosomally encoded β‑lactamases. In some isolates, plasmid‑borne AmpC β‑lactamase genes have been identified. Efflux pump overexpression, particularly of the RND family, can contribute to multidrug resistance, especially against fluoroquinolones and tetracyclines.
Susceptible Agents
Susceptibility testing indicates that third‑generation cephalosporins, carbapenems, and fluoroquinolones retain activity against the majority of clinical isolates. Aminoglycosides such as gentamicin and amikacin show good in vitro activity, though in vivo efficacy depends on pharmacokinetics and tissue penetration.
Treatment Guidelines
In the absence of specific guidelines for B. ansorpii, treatment is guided by susceptibility profiles and clinical judgment. For mild community‑acquired infections, oral third‑generation cephalosporins or fluoroquinolones may be effective. In severe or nosocomial cases, intravenous carbapenems or combination therapy with a β‑lactam/β‑lactamase inhibitor may be warranted.
Treatment and Management
Antibiotic Therapy
Empirical antibiotic regimens for community‑acquired pneumonia include β‑lactam/β‑lactamase inhibitor combinations or macrolide antibiotics. If B. ansorpii is identified, therapy should be tailored based on susceptibility data. For patients with impaired renal function or hepatic dysfunction, dosage adjustments are necessary to avoid toxicity.
Supportive Care
Supportive measures such as oxygen supplementation, bronchodilators, and corticosteroids are employed in severe respiratory cases. Fluid management and nutritional support are also critical components of comprehensive care, particularly in immunocompromised patients.
Monitoring and Follow‑Up
Serial chest imaging and sputum cultures are used to assess treatment response. Clinical improvement is generally observed within 5–7 days of appropriate antibiotic therapy, although persistent infection may require prolonged treatment or alternative regimens.
Management of Co‑infections
When B. ansorpii is isolated alongside other pathogens, combined antimicrobial coverage must address all identified organisms. Synergistic effects of antibiotic combinations are considered to prevent treatment failure and reduce the emergence of resistance.
Prevention and Control
Infection Control Practices
Standard infection control measures, including hand hygiene, use of personal protective equipment, and environmental cleaning, are effective in limiting the spread of B. ansorpii within healthcare facilities. Isolation precautions are recommended for patients with confirmed or suspected B. ansorpii infection, especially when accompanied by other resistant organisms.
Vaccination Status
There is no specific vaccine targeting B. ansorpii. However, routine immunization against other Bordetella species, particularly B. pertussis, may indirectly reduce respiratory tract colonization events and improve overall pulmonary health.
Environmental Controls
In environmental settings, routine disinfection of soil and water sources is not necessary for B. ansorpii due to its limited ecological impact. In laboratory environments, biosafety level 2 containment is adequate for routine culture and manipulation.
Public Health Surveillance
National surveillance programs for respiratory pathogens should include B. ansorpii to monitor emerging resistance patterns. Data sharing among institutions facilitates early detection of potential outbreaks and informs empirical therapy choices.
Epidemiology
Geographic Distribution
Case reports of B. ansorpii have been documented primarily in North America and Europe, with sporadic occurrences in Asia and Australia. The distribution appears to be related to sampling frequency rather than a true geographic bias.
Incidence and Prevalence
Reported incidence rates are low, estimated at less than 1 per 10,000 respiratory infections. Prevalence data are limited due to under‑reporting and diagnostic challenges. Large‑scale studies using PCR assays are needed to clarify the true burden of disease.
Risk Factors
Risk factors for infection include advanced age, underlying pulmonary disease (e.g., chronic obstructive pulmonary disease, cystic fibrosis), immunosuppression, and prolonged hospitalization. Recent antibiotic use may also predispose to colonization by opportunistic pathogens such as B. ansorpii.
Outbreak Investigations
No sustained outbreaks of B. ansorpii have been recorded. Most isolates arise from isolated clinical cases, suggesting limited transmissibility. Whole‑genome sequencing of outbreak‑related isolates would provide insight into transmission dynamics.
Research and Future Directions
Pathogenesis Studies
Functional genomics approaches, including transposon mutagenesis and RNA‑seq, are underway to identify essential virulence genes. Animal models, such as murine lung infection systems, will elucidate host‑pathogen interactions and disease mechanisms.
Diagnostic Innovations
Rapid, point‑of‑care molecular assays are being developed to improve detection of B. ansorpii directly from clinical specimens. CRISPR‑Cas‑based diagnostics may provide high specificity and sensitivity, reducing reliance on culture.
Antimicrobial Development
New antimicrobial agents targeting efflux pumps and β‑lactamases are in preclinical evaluation. Phage therapy and antimicrobial peptides represent alternative strategies to combat resistant B. ansorpii strains.
Vaccine Research
Exploratory vaccine candidates incorporating conserved outer membrane proteins are in the design phase. The feasibility of a cross‑species Bordetella vaccine could provide broad protection against respiratory tract infections.
Microbiome Impact
Studies exploring the role of B. ansorpii within the respiratory microbiome will clarify whether it acts as a commensal organism or a pathogenic disruptor. Metagenomic sequencing of lung microbiota may reveal ecological niches and competitive dynamics.
External Links
- Clinical Laboratory Standards Institute (CLSI) website – antimicrobial susceptibility guidelines.
- Centers for Disease Control and Prevention – respiratory pathogen surveillance.
- National Institute of Allergy and Infectious Diseases – research grants on bacterial pathogenesis.
- University of XYZ – laboratory for Bordetella genomics.
No comments yet. Be the first to comment!